DAFFODIL

The Treatment Reality of Type 2 diabetes Patients in Denmark 1995-2014 - A retrospective nationwide cohort study to investigate the treatment of patients with type 2 diabetes in Denmark.

There are recordings of approximately 320,000 persons in Denmark with diabetes (end of 2012), of which some 90% have type 2 diabetes (T2DM). Besides initial management and treatment of T2DM by lifestyle changes, many patients will eventually use oral and/or injectable glucose-lowering drugs. Comorbidities and events of side-effects have implications for prescription of these glucose-lowering drugs. New classes of glucose-lowering drugs have entered the market in Denmark since 2007, and there is scarce information on how the pattern of pharmacological treatment of T2DM has changed over the last two decades. 

Research questions and objectives: Incidence, prevalence and mortality rates of T2DM in Denmark. The study aims to map the pattern of pharmacological treatment of T2DM by describing the persistence, concomitant medication and switching over time and with an elucidation of patient characteristics including diabetes progression, comorbidities, side-effects, hospitalisations and retirement.

Design and method
A retrospective nationwide cohort study based on national registers at Statistics Denmark 

Target group
The study population covers all Danish residents with type 2 diabetes during 1995-2014, corresponding to 420,000 individuals.

Expected ending and outcome

End of 2016

Collaborators
AstraZeneca AB, Nordic-Baltic 

Sidst opdateret 14-02-2017

Responsible
Majken Linnemann Jensen
Clinical Epidemiology / Prediction and Prognosis

E-mail MLiJ@steno.dk
Phone + 45 30 75 73 82